TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

This study is ongoing, but not recruiting participants.

Study NCT00543725 Information provided by Tibotec Pharmaceuticals, Ireland

First Received: October 11, 2007 Last Updated: July 17, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	January 2011
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)